Agios Pharmaceuticals Stock (NASDAQ:AGIO)
Previous Close
$41.96
52W Range
$20.96 - $62.58
50D Avg
$49.73
200D Avg
$42.08
Market Cap
$2.23B
Avg Vol (3M)
$760.82K
Beta
0.75
Div Yield
-
AGIO Company Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Performance
Revenue Breakdown
Peer Comparison
Ticker | Company |
---|---|
CGEM | Cullinan Oncology, Inc. |
RVMD | Revolution Medicines, Inc. |
KALV | KalVista Pharmaceuticals, Inc. |
BPMC | Blueprint Medicines Corporation |
ANAB | AnaptysBio, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
STOK | Stoke Therapeutics, Inc. |
COGT | Cogent Biosciences, Inc. |
BDTX | Black Diamond Therapeutics, Inc. |
PLRX | Pliant Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
NRIX | Nurix Therapeutics, Inc. |
KYMR | Kymera Therapeutics, Inc. |
ARVN | Arvinas, Inc. |
IDYA | IDEAYA Biosciences, Inc. |
MREO | Mereo BioPharma Group plc |
KROS | Keros Therapeutics, Inc. |
MGTX | MeiraGTx Holdings plc |
BMRN | BioMarin Pharmaceutical Inc. |
CCCC | C4 Therapeutics, Inc. |
SNDX | Syndax Pharmaceuticals, Inc. |
MRSN | Mersana Therapeutics, Inc. |